Influence of HIV infection on mortality in a cohort of patients treated for tuberculosis in the context of wide access to HAART, in Rio de Janeiro, Brazil

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 5, 2009, Pages 623-628

  Schmaltz, Carolina Arana Stanis ^a,b   Sant'Anna, Flávia Marinho ^a   Neves, Simone Carvalho ^a   Velasque, Luciane De Souza ^a   Lourenço, Maria Cristina ^a   Morgado, Mariza Gonçalves ^c   Rolla, Valéria Cavalcanti ^a   Lopes, Guilherme Santoro ^b  

^a Funda??o Oswaldo Cruz   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Brazil; HAART; HIV; Mortality; Tuberculosis

Indexed keywords

EFAVIRENZ; ETHAMBUTOL; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STREPTOMYCIN; ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BRAZIL; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SEROLOGY; SOCIAL STATUS; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD; AIDS RELATED COMPLEX; COMPARATIVE STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; BRAZIL; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS;

EID: 73349095069     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b31e56     Document Type: Article

References (38)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269-1276.
2. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009-1021.
3. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS. 2000;14:1985-1991.
4. Jones JL, Hanson DL, Dworkin MS, et al. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis. 2000;4: 1026-1031.
5. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002; 359:2059-2064.
6. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS. 2005;19:2109-2116.
7. Brinkhof MW, Egger M, Boulle A, et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis. 2007;45:1518-1521.
8. Miranda A, Morgan M, Jamal L, et al. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS ONE. 2007;2:e826.
9. Muga R, Ferreros I, Langohr K, et al. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS. 2007;21:2521-2527.
10. Girardi E, Palmieri F, Cingolani A, et al. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antire-troviral therapy. J Acquir Immune Defic Syndr. 2001;26:326-331.
11. Carvalho AC, Nunes ZB, Martins M, et al. Clinical presentation and survival of smear-positive pulmonary tuberculosis patients of a university general hospital in a developing country. Mem Inst Oswaldo Cruz. 2002; 97:1225-1230.
12. Garcia de Olalla P, Martinez-Gonzalez MA, Cayla JA, et al. Influence of highly active anti-retroviral therapy (HAART) on the natural history of extra-pulmonary tuberculosis in HIV patients. Int J Tuberc Lung Dis. 2002;6:1051-1057.
13. Dheda K, Lampe FC, Johnson MA, et al. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis. 2004;190:1670-1676.
14. Manosuthi W, Chottanapand S, Thongyen S, et al. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;43:42-46.
15. Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med. 2007;175:1199-1206.
16. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998;158:157-161.
17. Navas E, Martin-Davila P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med. 2002;162:97-99.
18. Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax. 2004;59:704-707.
19. Lawn SD, Myer L, Orrell C, et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19:2141-2148.
20. Lanternier F, Dalban C, Perez L, et al. Tolerability of anti-tuberculosis treatment and HIV serostatus. Int J Tuberc Lung Dis. 2007;11:1203-1209.
21. Pukenyte E, Lescure FX, Rey D, et al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2007;11:78-84.
22. Cayla JA, Caminero JA, Rey R, et al. Current status of treatment completion and fatality among tuberculosis patients in Spain. Int J Tuberc Lung Dis. 2004;8:458-464.
23. Sterling TR, Zhao Z, Khan A, et al. Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis. 2006;10:542-549. (Pubitemid 43667643)
24. Saraceni V, King BS, Cavalcante SC, et al. Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis. 2008;12:769-772.
25. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA. 1984; 252:1905-1907.
26. Castelo A, Kritski AL, Barreto AW, et al. II Consenso Brasileiro de Tuberculose. J. Bras Pneumol. 2004;30(Suppl 1):S24-S37.
27. Ministério da Saúde do Brasil. Recomendaxcões Para Terapia Anti-Retroviral Em Adultos Infectados Pelo HIV. 7a ed. Brasilia, Brazil: Programa Nacional de DST e Aids 2008.
28. Nunn P, Brindle R, Carpenter L, et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality. Am Rev Respir Dis. 1992; 146:849-854.
29. Elliott AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg. 1995;89:78-82.
30. Whalen C, Horsburgh CR Jr, Hom D, et al. Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. AIDS. 1997;11:455-460.
31. Gonzalez OY, Adams G, Teeter LD, et al. Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis. Int J Tuberc Lung Dis. 2003;7:1178-1185.
32. Kwara A, Roahen-Harrison S, Prystowsky E, et al. Manifestations and outcome of extra-pulmonary tuberculosis: impact of human immunodeficiency virus co-infection. Int J Tuberc Lung Dis. 2005;9:485-493.
33. DeRiemer K, Soares EC, Dias SM, et al. HIV testing among tuberculosis patients in the era of antiretroviral therapy: a population-based study in Brazil. Int J Tuberc Lung Dis. 2000;4:519-527.
34. Souza FB, Villa TC, Cavalcante SC, et al. Peculiarities of tuberculosis control in a scenario of urban violence in a disadvantaged community in Rio de Janeiro, Brazil. J Bras Pneumol. 2007;33:318-322.
35. Greenberg AE, Lucas S, Tossou O, et al. Autopsy-proven causes of death in HIV-infected patients treated for tuberculosis in Abidjan, Cote d'Ivoire. AIDS. 1995;9:1251-1254.
36. Murray J, Sonnenberg P, Shearer SC, et al. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med. 1999;159: 733-740.
37. Churchyard GJ, Kleinschmidt I, Corbett EL, et al. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2000;4:705-712.
38. Gutierrez EB, Zanetta DM, Saldiva PH, et al. Autopsy-proven determinants of death in HIV-infected patients treated for pulmonary tuberculosis in Sao Paulo, Brazil. Pathol Res Pract. 2002;198:339-346.